A Phase II Study of Sorafenib (Nexavar) Prior to Radical Prostatectomy in Patients With High-Risk Localized Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 08 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.